IJSSRA l ISSN (online): 3107-6238
January-March 2026 l Vol. 1 l Issue 4

Cancer in the Modern Era: Emerging Patterns, Key Challenges, and Future Perspectives

***Dr. Parvati Kushram[1] & Brajesh Singh[2]**

*[1]Associate Professor, Government Chandravijay PG College, Dindori, Madhya Pradesh
E-Mail: drparvatikushram@gmail.com
[2]Assistant Professor, Government Chandravijay PG College, Dindori, Madhya Pradesh
E-Mail: Brijeshd332@gmail.com
DOI: https://doi.org/10.5281/zenodo.20833959

Abstract

Cancer continues to be a major public health threat globally, presenting a large-scale problem for global health systems. The disease's epidemiology has undergone many changes in recent years, with rising rates of lifestyle related cancers (breast, lung, colon and prostate). Urbanization, demographic shifts, and growing population exposures to pollutants have contributed greatly to this trend. Furthermore, there is growing evidence that the onset age for cancers is decreasing. The aim of this review article will be to examine the current state of cancer; look at new trends, identify problems in controlling the disease, and examine what can happen next. Late diagnoses due to limited or no screenings available, lack of knowledge about the disease in lower resource environments, cost of treatments, side effects from drugs, and lack of medical facilities all lead to poor outcomes when trying to address inequalities in cancer survival across different geographic locations. While some issues exist because of lack of money and resources, they are being addressed. New technologies like precision medicine, immune therapy, AI-based diagnostic tools, liquid biopsies, and nanomedicine based targeted release platforms are becoming increasingly popular. All of these allow doctors to detect cancers sooner than before, improve accuracy in diagnosis and develop personalized treatment plans for each individual.

Keywords: *Cancer Epidemiology, Precision Medicine, Immunotherapy, Early Detection, Cancer Prevention, Global Health Disparities.*

Introduction

Cancer represents one of the greatest threats to health today; it results in thousands of deaths around the globe and places a great deal of stress on people, families, healthcare facilities, and all levels of society. Each year millions of new cancer diagnoses are made and millions of people die from this disease. The numbers of people diagnosed and dying from cancer have increased over the years as the world's population ages. Many factors contribute to an increase in cancer incidence and death such as the use of tobacco, alcohol, lack of physical activity, poor diet, pollution, etc. Survival rates for some cancers have improved with better detection and treatment methods but inequities continue to exist between wealthy and impoverished nations that do not have equal access to healthcare.

Researching the growing number of people getting cancer today has become very important for researches, policy makers, and health care providers. There is a changing pattern of different cancers occurring today. Also, many young adults are being diagnosed with cancer. And within regions and communities, there are social-economic and environmental influences that may impact whether or how often people get cancer. Understanding these will help identify what increases the risk of someone developing cancer. It will also give us information about ways we can improve prevention measures and provide better treatments.

Evolution of Cancer Epidemiology

The field of cancer epidemiology has evolved dramatically over the last hundred years, as well as broader aspects of world health trends, demography, and environmental characteristics. Historically, cancer was regarded as one of the less prevalent causes of death when compared to other infectious diseases like tuberculosis, pneumonia, and malaria. However, because of advances in sanitation practices; vaccinations; antibiotic treatments; and development of public health infrastructures around the globe, there has been a decrease in deaths from infectious diseases, which resulted in an increased trend toward non-communicable diseases (NCD's) --including cancer--as predominant causes of death. Prior to recent advances in medical technology, cancer incidence and survivorship statistics were often lacking data due to lack of diagnostic capabilities and inadequate reporting mechanisms. Many individuals died from their cancer diagnosis prior to receiving treatment due to delayed diagnoses that occurred during advanced stages of the disease. Advances in medical imaging technologies; pathological techniques; and the implementation of screening methods have greatly enhanced the ability for earlier identification of various forms of cancer, thus increasing survivorship for certain forms of cancer such as breast, prostate, and colon/rectal cancers. While improvements in cancer survivorship statistics do reflect increased early detection efforts, it also reflects actual increases in the occurrence rate of cancer worldwide. One of the most critical transitions in cancer epidemiology relates to the transition from infectious disease as a primary concern to NCD's. The nature of this transition is directly related to the process of industrialization, urbanization and the adoption of new lifestyles by populations. As countries undergo economic growth, there will be a corresponding transition in the type of diseases that create a burden on society. Diseases that affect younger members of society such as tuberculosis; malaria; and diphtheria will continue to decline in prevalence; whereas diseases that primarily affect older adults such as heart disease; stroke; and cancer will increase.

Demographic transitions have also influenced cancer epidemiology. In addition to an increase in average life expectancy, there are changes occurring within some demographic categories (such as those in developing countries); as a result of demographic shifts; there is a resultant increase in the

number of people who are at risk for developing cancer. Lifestyle factors and environmental exposures have emerged as the most relevant topics to understand contemporary trends in cancer. Tobacco use; alcohol consumption; unhealthy diets; sedentary behavior and increasing body mass index (BMI) contribute to cancer risk. Exposure to pollutants in the air we breathe; chemical exposures from industry; radiation; and occupational hazards all add additional layers of risk for developing cancer.

Emerging Patterns of Cancer

The last few years have seen many transformations in how we understand the incidence, distribution and demographics of cancer around the world. Many of these new trends are a result of the interaction of genetics (susceptibility), environment (exposures) as well as lifestyle (changes) and advances in medical care. Identifying these evolving trends will be critical to developing the most effective methods for preventing, detecting early, and treating cancers in today's society.

Changing Cancer Types

One of the most prominent emergent patterns in oncology is the shift in the cancer type spectrum. Globally, there has been a substantial increase in breast, lung, colorectal and prostate cancers. These cancers are now among the most commonly diagnosed malignancies worldwide. For example, breast cancer is now the leading cause of cancer diagnosis among women in many countries due to factors such as changes in the way we have children today, delayed first births, hormonal factors and our lifestyle choices. Similarly, the incidence of prostate cancer among men has also risen, partially due to improved screening techniques like psa testing as well as longer life expectancy. Lung cancer continues to be One of the leading causes of death from cancer worldwide. While smoking remains the primary risk factor for developing lung cancer, non-smoking-related cases of lung cancer are also increasing, especially among women and people who do not smok which suggests that environmental pollution and genetic predisposition may play a role. Colon cancer is also on the rise, particularly in urban populations, and is strongly associated with our diets, level of physical activity and obesity.

Early Onset Cancer Trends

The incidence of Cancer among young adults has become one of many growing concerns. For years, it has been accepted that Cancers like Colorectal, Breast and Gastric were a disease typically of older people; however, over recent times they have been identified with increasing frequency in Younger Adults (people under the age of 50). There are several theories as to why we are seeing a rise in Early-Onset Cancers. In some cases, genetics play a major part. The most obvious example would be hereditary cancer syndrome. Environmental and Lifestyle factors are also becoming more prominent. Diet changes, Obesity rates on the increase, less time spent physically active and higher levels of environmental toxins are just a few examples of how our lifestyle choices could be contributing to

Carcinogens earlier than ever before. More recently, researchers have started looking into the possibility of Gut Microbiota and Chronic Inflammation playing a larger role in the development of these types of Cancers.

Early On-Set Cancers tend to grow faster and by the time they are found, they have progressed further along in their development. Many are likely to go undiagnosed until late stage because of the fact that both younger patients and Physicians are less likely to suspect the diagnosis of Cancer in someone of this demographic. As such, there will need to be new Screening Guidelines put into place and Awareness campaigns developed to alert the Younger Populations about the risks associated with Cancer.

Role of Lifestyle and Environment

Lifestyle and environmental influences are becoming key elements in the evolving landscape of cancer epidemiology. Tobacco is still the number one preventable cause of cancer in the world and contributes to the incidence of cancers of the lungs, mouth, throat and bladder. Campaigns against smoking globally continue to have limited success due to tobacco's continued presence as a major public health problem in many developing countries.

Consumption of diets that include excessive amounts of processed foods, red meat, sugar, and fat while consuming less fruit and vegetable intake, is associated with increased risks for many types of cancers. Obesity also poses a unique threat to development of tumors through hormonal imbalance and chronic inflammation. Another proven risk factor for cancer is alcohol. This is because alcohol has been shown to contribute to an elevated rate of cancer for the liver, breast, esophagus, and colon when consumed alone or used in combination with tobacco. Increased exposure to pollutants from the environment, including air quality, contaminated water, and chemical compounds from industry has become an ever-increasing concern for cancer. Exposure levels are greater in urban industrialized regions to carcinogens like particulates, heavy metals, and toxic gases. Workers' occupational exposures to carcinogens during work in mines, construction and manufacturing increase their potential for cancer.

Key Challenges in Cancer Control

Although, there have been great advances in cancer care, controlling cancer is still an enormous problem in terms of global public health. Due to the complexities of the biological processes involved in cancer development along with socioeconomic disparities and shortages in the availability of adequate healthcare systems, it is challenging to prevent cancer, detect cancer at an early stage and effectively treat many cancers throughout much of the world. Some of the most important challenges associated with cancer control are that cancer is diagnosed too late for treatment; that there are large gaps in access to screening services and that treatments can be inaccessible due to their cost; that

drugs may not work well or may fail; and that many countries lack sufficient and effective healthcare infrastructure.

Late Diagnosis and Screening Gaps

One of the biggest obstacles to effective cancer control is that cancer is diagnosed too late. A significant number of cancer diagnoses occur at later stages when treatment options are limited and survival chances decrease. The earlier detection of cancer can lead to better patient outcomes; however, there currently are inadequate national screening programs for the four most prevalent cancers (breast, cervix, colon/prostate). There is no universal system for organized screening, which results in the delayed identification of abnormal cells or small tumors that may eventually develop into cancer. Cervical cancer is one type of cancer where there are highly effective methods of prevention/treatment if it is identified before it progresses. Unfortunately, in many low/middle income countries, these types of screening programs do not exist or they are poorly administered. Lack of education regarding the public's role in preventing/early detecting cancer is another major obstacle. Low resource populations typically have little information on the early warning signs of cancer or the benefits of routine medical check-ups. Stigma, fear of being diagnosed with cancer, and cultural norms also discourage patients from obtaining early medical care. Therefore, by the time a patient presents to a healthcare facility their symptoms will be severe enough to indicate that the cancer has progressed to a late stage.

Treatment Accessibility and Cost

Cancer is treated very inequitably worldwide in terms of the effectiveness of cancer therapy, by region and demographic. While modern cancer therapies such as; chemotherapy, radiotherapy, immunotherapy, and targeted therapies provide for improved survival from cancer, many of these new therapies can be prohibitively expensive to the majority of the world’s population.

These expenses place an unsustainable burden on patients and their families resulting in what is referred to as "catastrophic" levels of healthcare spending. Even in those countries that have some form of government sponsored universal healthcare system, there is often limited availability of state-of-the-art medical care to only certain geographic areas (i.e., metropolitan urban settings), which leaves many rural populations without adequate or any access to quality cancer diagnosis and/or treatment. This additional layer of healthcare disparities also adds to the inequity of access to quality cancer care. The difference in the level of technology used to diagnose and treat cancer varies widely between high income/developed countries where patients have ready access to the latest technologies and personalization of treatment options and low income/developing countries where there are shortages of available medications, long delays before receiving appropriate treatment, and lack of supportive care services.

Drug Resistance and Treatment Failure

A further challenge facing cancer control is drug resistance, resulting in ineffective treatments for many patients. Tumors exhibit marked genetic and biological variation, which can be due to heterogeneity of cancer cells. The ability to develop resistant cells allows tumors to continue growing after being treated with drugs; this results in relapse of the cancer.
In addition to chemo-therapy and targeted therapy, resistance to immunotherapy is increasingly concerning in the field of oncology. Resistance mechanisms include: (1) genetic mutations in the cancer cells, (2) activation of alternative cell signaling pathways and (3) alterations in drug metabolism. As an illustration of mechanism-based adaptation, cancers have developed resistance to previously effective targeted therapies. The development of resistance mechanisms makes it difficult to achieve long term control of cancers. Despite continued research into understanding resistance mechanisms and developing combination therapeutic strategies that will either prevent or significantly delay the onset of treatment failures, implementing these new combinations in the clinic continues to be cost-prohibitive.

Healthcare Infrastructure Limitations

The biggest barriers to cancer control are weak health systems in developing world areas. There are too few professionals who can provide training as an oncologist (medical, radiation, pathology), there are too few oncology nurse. The number of professionals that are available will limit how quickly and efficiently the system will be able to identify and treat cancer. Cancer treatment is also limited due to the fact that cancer treatment has been concentrated into a handful of large cities in low resource settings. For people living outside of those cities, this makes it difficult to get cancer diagnosed/treated because they have to travel far away from their homes, may have no way to get to where treatment is located, and when they do finally make it to a hospital/clinic, they often have long wait times due to the over-crowding at these locations.

A major limitation to being able to understand disease patterns and evaluate intervention efforts by creating targeted cancer control programs is the lack of reliable data through cancer registries. Many developing countries do not have a strong, well-maintained cancer registry system. Without reliable data on what types of cancers exist in a country, and where, policymakers are unable to effectively allocate funds/resources to fight cancer.

Precision Medicine and Genomics

Precision Medicine is a new paradigm in cancer therapy which utilizes a patient's genetic information, as well as other aspects of their environment, to tailor treatments to each patient individually. The rapidly expanding field of Genomics has provided the basis for researchers to identify the many genetic mutations and molecular changes that contribute to the formation of cancers. Next generation

sequencing (NGS), a powerful method for analyzing large amounts of DNA sequence data, allows researchers to analyze the entire DNA sequence of tumors and thus choose targeted therapies against specific mutations. This approach provides better treatment outcomes with fewer adverse reactions than traditional "one size fits all" cancer treatments.

Immunotherapy and Targeted Therapy

Immunotherapy is a new way of treating many types of cancer by using your own immune system to find and kill your own cancer cells. The most common examples of immunotherapies are cancer vaccines, Immune Checkpoint Inhibitors and CAR-T Cell Therapy. CAR-T Cell Therapy, Cancer Vaccines and Immune Checkpoint Inhibitors have had some very successful results in Melanoma, Lung Cancer and Lymphoma. Immunotherapies work by allowing the body's immune system to recognize and fight against its own cancer cells; because they allow the body's immune system to see that it should fight these cancer cells.

Unlike traditional Chemotherapy treatments that target all cells (healthy & unhealthy) within the body, Targeted Therapies can focus on a single protein or gene at the root of what makes tumors grow and advance. This approach can lead to much lower toxicity for patients while still being effective. There are several examples of drugs that specifically target genetic mutations including EGFR, HER2 and BRAF.

Artificial Intelligence in Cancer Diagnosis

Increasingly artificial intelligence (AI) is being added to oncology to provide a better outcome through improved diagnosis, prediction and planning. The machine learning algorithms are able to determine if there are abnormalities within the medical imaging of CT scans, MRI's and Histopthological slides at an extremely high rate of success over the clinician. The AI will assist in predicting the disease progression, how well the treatment works and how the patients will do based on all data from large sets of information. This technology will increase the diagnostics, reduce work load for clinicians, and improve detection of cancers earlier.

Liquid Biopsy and Biomarker Discovery

The liquid biopsy technology uses a non-invasive process to detect biomarkers like ctDNA, exosomes or CTCs in blood, which are associated with cancer. The liquid biopsy can be used for the continual assessment of how tumors grow over time; therefore, it has been used for early diagnosis of recurrences and the evaluation of treatment responses.

Liquid Biopsy Biomarker Discovery: The identification of the molecular determinants of cancer risk, disease prognosis, and therapeutic responsiveness are major contributors to the development of patient-specific diagnostic techniques and treatments. Patient-specific diagnostic techniques and treatments enable clinicians to stratify patients based on their cancer type and develop effective

treatment plans, while decreasing the number of patients who receive ineffective medical interventions.

Nanotechnology in Drug Delivery

Nanotechnology has created new avenues for treating cancers through developing better drug delivery systems. The drug (anticancer) is delivered using nanoparticles that target a specific area of the body (the tumor), which increases the drug concentration in the cancerous cells and decreases the number of toxic substances in healthy cells. Using nanoparticles to target cancerous cells enables treatments to be effective at lower dosages than those typically used in chemotherapy; this results in fewer side effects. Liposomes, dendrimers, and polymer-based nanoparticles are examples of the types of "nanocarriers" that are currently being studied and developed for their potential in controlling drug delivery. Many forms of nanomedicine are also being tested or have been approved for use in clinics.

Future Perspectives in Cancer Research and Management

Cancer research is rapidly evolving, driven by technological advancements, improved understanding of tumor biology, and increasing global collaboration. Despite significant progress, the global cancer burden continues to rise, necessitating innovative and sustainable strategies for prevention, diagnosis, and treatment. The future of cancer control is expected to be shaped by personalized medicine, digital health technologies, affordable treatment innovations, strengthened surveillance systems, and a strong emphasis on prevention and early detection.

Personalized Cancer Treatment Approaches

One area that has great potential for advancements in oncology is the personalization/precision cancer therapy approach. Precision or personalized medicine utilizes all available information about an individual (genetic makeup, tumor biology, lifestyle habits and environmental exposures) to create a tailored course of treatment. Recent advances in molecular biology and genomics allow for the identification of discrete genetic mutations responsible for the development of cancer. The expectation is that cancer treatment will become increasingly customized through the utilization of genomic profiling and biomarkers-based treatments. Clinicians will no longer utilize generic standard chemotherapy regimen; instead, they will utilize medications that target specifically the molecular cause of their patients' cancers. Not only should this increase efficacy of the treatment options used, but decrease side effects from those treatments. Additionally, recent advances in gene editing technology (CRISPR), and personalized immunotherapy approaches are expected to revolutionize how we manage cancer.

Development of Affordable Cancer Therapies

One of the biggest hurdles in international oncology is how much many treatments for cancer cost. The majority of these new "advanced" or "cutting edge" treatments, such as immunotherapies,

targeted drug therapies, etc., are too expensive for large portions of the population, particularly in lower-middle income countries. It is therefore crucial to create affordable cancer therapies in the near future. Costs have been reduced by developing Biosimilars (generics) for very expensive drugs, and locally produced cancer medications. The use of public private collaborations and global health programs could significantly enhance both the affordability and availability of cancer therapies. In addition, there has recently been growing interest in utilizing current inexpensive drugs to treat various cancers as one of the most feasible strategies for reducing cancer therapy costs.

Focus on Prevention and Early Detection Strategies

Prevention and early detection of Cancer will be a continuing low-cost strategy to reduce the World-wide burden of Cancer. Future Strategies for Controlling Cancer will also include increasing focus on Lifestyle Changes and Vaccinations and Early Detection by Screening Programs. In order to decrease the incidence of Cancer, Public Health Campaigns are needed that target smoking cessation; Healthy Eating Promotions and Physical Activity Promotions and Obesity Reduction Initiatives. The Vaccines for Cervical Cancer (Human Papilloma Virus Vaccine) and Liver Cancer (Hepatitis B Vaccine) are two examples of very effective Preventive Measures.

Importance of Awareness and Education Programs

Cancer prevention is based on public awareness and health education. As many cancers are identified as late-stage (due to lack of awareness of early signs/symptoms and/or other risk factors), educational programs will provide the means for individuals to take on a healthy lifestyle; identify potential warning signs; and seek out proper medical assistance in a timely manner. The efforts by community-based awareness campaigns, school education programs, and mass media programs all have an important part in educating people about cancer prevention. Awareness of cancer can also lead to decreased stigma related to cancer and increased involvement in screening.

Screening and Vaccination Programs

Screening programs are essential for early detection of cancer which provides the best opportunity for successful treatment. Programs for organized screening have proven to be effective in significantly lowering death rates from breast cancer (via mammography), cervical cancer (through Pap smear and HPV testing), and colorectal cancer (through colonoscopy or fecal based tests). Vaccines also contribute greatly to preventions against certain cancers. Vaccinations of the HPV vaccine have shown to be very effective in the prevention of cervical cancer, while vaccinations with the Hepatitis B Vaccine show a significant reduction in liver cancer. Improving access to these vaccines is a critical public health goal, especially in lower income areas.

Research Gaps in Cancer Studies

- One of the most significant limitations in global cancer research today is the paucity of complete data from low-income and middle-income countries. In too many parts of the world, there are no established cancer registries, which creates gaps in reporting and therefore hampers our ability to completely understand the ways that different types of cancer occur. The absence of global data has significantly hindered efforts to create viable international strategies for controlling cancer.
- The issues with collecting global data, we also require additional longitudinal cohorts to enhance our knowledge of how cancers arise, progress, and lead to patient outcomes. These cohort studies provide us with critical information about the causative mechanisms of various risk factors associated with cancers and help assess the effectiveness of cancer prevention programs over extended time periods. Unfortunately, these cohort studies are expensive and typically difficult to fund in lower income areas of the world.
- Under-research rare cancer types while breast, lung, and colon cancers have received extensive study, many rarer or regional types of cancers receive little to no research. As a result of this limited research into rare types of cancers, we still have much to learn about the causes, behaviors, and potential treatments for these cancers. Therefore, it will be important to devote increased resources towards the study of rare cancers and other types of cancers found predominantly within certain populations.
- Limited integration across datasets (omics) As cancer research moves into an era of greater use of multi-omics approaches (e.g., genomics, proteomics, metabolomics, transcriptomics), however, there continue to be challenges both technologically and analytically when integrating across different omic datasets. Further analysis using more integrated multi-omic approaches will ultimately allow researchers to gain a deeper understanding of the biological behavior of tumors and thus develop truly individualized therapeutic regimens.

Conclusion

Cancer continues to be a very serious issue for individuals worldwide and places an extreme burden on both global health systems and economies. This article discusses recent developments in cancer research, its management and how they may influence future areas of study. It emphasizes the fact that cancer is a very heterogenous group of diseases; each form of cancer has different risk factors including genetics, environment, lifestyle and socio-economic status. The number of cases of lifestyle related cancers (breast, colon, lung, prostate) are increasing dramatically. There is strong evidence that this increase is directly related to increased urbanization, diets that have become increasingly unhealthy, obesity, lack of exercise, smoking and drinking. There is also growing concern regarding

an increased rate of early onset cancer cases among younger people. This indicates a deviation from previously observed cancer patterns by age.

There is also substantial geographic inequality in terms of the burden and outcome of cancer. Countries with developed health care systems tend to report higher rates of cancer incidence than countries with less advanced health care systems because their patients receive earlier and more accurate diagnoses and treatment, resulting in improved survival rates. Conversely, countries with underdeveloped health care systems experience significantly higher rates of cancer mortality because they do not have adequate screening or diagnostic capabilities, have limited access to treatments and have poorly equipped health care infrastructures. Additionally, the quality of health care services tends to be greater in cities than rural areas which exacerbates existing inequities. The primary barriers to controlling the cancer epidemic are delays in diagnosis stemming from poor access to screening programs, exorbitant costs associated with treatment options, rapid development of chemoresistance and inadequacies in health care delivery. The lack of available trained professionals to provide oncology care and ineffective cancer registration systems add additional barriers to the implementation of successful cancer management practices in resource-poor environments.

Despite the many challenges facing those working towards controlling the global cancer epidemic there are several new technologies being implemented into clinical practice that will likely lead to improvements in cancer care. Precision medicine, immunotherapy, AI and advances in early detection diagnostics represent some of the new technologies that are changing the way we treat cancer. Personalized therapy regimens that take into account the individual's unique characteristics and genetic makeup are expected to play a major role in improving the efficacy of our current treatments. Affordable drugs that can be accessed throughout the world will also play a major role in reducing the disparity currently seen in cancer outcomes. Improved global surveillance systems will facilitate identifying at-risk populations thereby allowing for earlier intervention through education and public awareness campaigns. Finally, improved public education about cancer risk reduction and prevention will ultimately result in fewer new cases of cancer being diagnosed annually.

References:

1. Nwosu, N. (2024). Cancer: A Disease of Modern Times?. Cureus, 16(11).
2. Varmus, H. (2006). The new era in cancer research. Science, 312(5777), 1162-1165.
3. Song, Q., Merajver, S. D., & Li, J. Z. (2015). Cancer classification in the genomic era: five contemporary problems. Human genomics, 9(1), 27.
4. Chanu, M. T., & Singh, A. S. (2022). Cancer disease and its' understanding from the ancient knowledge to the modern concept. World J. Adv. Res. Rev, 15(2), 169-176.

5. Greer, J. A. (2016). Challenge of prognostic uncertainty in the modern era of cancer therapeutics. Journal of Clinical Oncology, 34(30), 3605-3608.
6. Van Dyke, T., & Jacks, T. (2002). Cancer modeling in the modern era: progress and challenges. Cell, 108(2), 135-144.
7. Varghese, A. M., Arora, A., Capanu, M., Camacho, N., Won, H. H., Zehir, A., ... & Saltz, L. B. (2017). Clinical and molecular characterization of patients with cancer of unknown primary in the modern era. Annals of Oncology, 28(12), 3015-3021. Jasra, S., & Anampa, J. (2018). Anthracycline use for early-stage breast cancer in the modern era: a review. Current treatment options in oncology, 19(6), 30.
8. Subramaniam, A., Fauci, J. M., Schneider, K. E., Whitworth, J. M., Erickson, B. K., Kim, K., & Huh, W. K. (2011). Invasive cervical cancer and screening: what are the rates of unscreened and underscreened women in the modern era?. Journal of lower genital tract disease, 15(2), 110-113.
9. Fatima, A. (2021). Epidemiology, Types, and Diagnosis of Cancer in Modern Era. Pulsus J. Surg. Res, 5(4).
10. Li, Y., Jiang, Y., Qiu, B., Sun, H., & Wang, J. (2022). Current radiotherapy for recurrent head and neck cancer in the modern era: a state-of-the-art review. Journal of Translational Medicine, 20(1), 566.
11. Haylock, P. J. (2011, November). Cancer nursing: the modern era. In Oncology Nursing Forum (Vol. 38).
12. Hut, A. R., Boia, E. R., Para, D., Iovanescu, G., Horhat, D., Mikša, L., ... & Balica, N. C. (2025). Laryngeal cancer in the modern era: evolving trends in diagnosis, treatment, and survival outcomes. Journal of Clinical Medicine, 14(10), 3367.
13. Takayama, S., Wakasugi, T., Funahashi, H., & Takeyama, H. (2010). Strategies for gastric cancer in the modern era. World Journal of Gastrointestinal Oncology, 2(9), 335.